The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
Expansion of CAG trinucleotide repeat within the coding region of several genes results in the production of proteins with expanded polyglutamine (PolyQ) stretch. The expression of these pathogenic proteins leads to PolyQ diseases, such as Huntington's disease or several types of spinocerebellar ataxias. This family of neurodegenerative disorders is characterized by constant progression of the symptoms and molecularly, by the accumulation of mutant proteins inside neurons causing their dysfunction and eventually death. So far, no effective therapy actually preventing the physical and/or mental decline has been developed. Experimental therapeutic strategies either target the levels or processing of mutant proteins in an attempt to prevent cellular deterioration, or they are aimed at the downstream pathologic effects to reverse or ameliorate the caused damages. Certain pathomechanistic aspects of PolyQ disorders are discussed here. Relevance of disease models and recent knowledge of therapeutic possibilities is reviewed and updated.
Bauer
Peter O
PO
Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, Saitama, Japan.
Nukina
Nobuyuki
N
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D009154:Mutation / Q000235:genetics*; D009419:Nerve Tissue Proteins / Q000235:genetics; D019636:Neurodegenerative Diseases / Q000145:classification / Q000235:genetics* / Q000628:therapy*; D010455:Peptides / Q000235:genetics*; D017510:Protein Folding; D019680:Trinucleotide Repeat Expansion / Q000235:genetics*
D009419:Nerve Tissue Proteins; D010455:Peptides; C097188:polyglutamine